Uric acid as a danger signal in gout and its comorbidities

Uric acid is a waste product of purine catabolism. This molecule comes to clinical attention when it nucleates to form crystals of monosodium urate (MSU) in joints or other tissues, and thereby causes the inflammatory disease of gout. Patients with gout frequently suffer from a number of comorbid conditions including hypertension, diabetes mellitus and cardiovascular disease. Why MSU crystals trigger inflammation and are associated with comorbidities of gout has been unclear, but recent studies provide new insights into these issues. Rather than simply being a waste product, uric acid could serve a pathophysiological role as a local alarm signal that alerts the immune system to cell injury and helps to trigger both innate and adaptive immune responses. The inflammatory component of these immune responses is caused when urate crystals trigger both inflammasome-dependent and independent pathways to generate the proinflammatory cytokine IL-1. The resulting bioactive IL-1 stimulates the inflammation of gout and might contribute to the development of other comorbidities. Surprisingly, the same mechanisms underlie the inflammatory response to a number of irritant particles, many of which also cause disease. These new insights help to explain the pathogenesis of gout and point to potential new therapeutic targets for this and other sterile inflammatory diseases.

[1]  Per Axel Clausen,et al.  Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. , 2011, ACS nano.

[2]  T. Roger,et al.  Basic Calcium Phosphate Crystals Induce Monocyte/Macrophage IL-1β Secretion through the NLRP3 Inflammasome In Vitro , 2011, The Journal of Immunology.

[3]  J J Padgett,et al.  A renewed sense of self. , 1994, Journal of psychosocial nursing and mental health services.

[4]  L. French,et al.  Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression , 2011, Proceedings of the National Academy of Sciences.

[5]  H. Kawasaki,et al.  Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[7]  M. Elisaf,et al.  Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? , 1997, The Journal of laboratory and clinical medicine.

[8]  Melinda K. Kutzing,et al.  Altered Uric Acid Levels and Disease States , 2008, Journal of Pharmacology and Experimental Therapeutics.

[9]  Fernando Ontiveros,et al.  The sterile inflammatory response. , 2010, Annual review of immunology.

[10]  M. Elisaf,et al.  Elevated interleukin‐1β in the circulation of patients with essential hypertension before any drug therapy: a pilot study , 1996, European journal of clinical investigation.

[11]  Jonathan L. Schmid-Burgk,et al.  Inflammasomes: current understanding and open questions , 2011, Cellular and Molecular Life Sciences.

[12]  G. Hollingworth,et al.  Comparison of injection techniques for shoulder pain: results of a double blind, randomised study. , 1983, British medical journal.

[13]  E. Remmers,et al.  De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. , 2002, Arthritis and rheumatism.

[14]  J. Tschopp,et al.  The Inflammasomes , 2010, Cell.

[15]  G. Gamble,et al.  Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout , 2011, Annals of the rheumatic diseases.

[16]  D. Hazuda,et al.  Processing of Precursor Interleukin 18 and Inflammatory Disease * , 2001 .

[17]  K. Rock,et al.  Innate and adaptive immune responses to cell death , 2011, Immunological reviews.

[18]  D. Hazuda,et al.  Processing of precursor interleukin 1 beta and inflammatory disease. , 1990, The Journal of biological chemistry.

[19]  Egil Lien,et al.  NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.

[20]  P. Kovanen,et al.  Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation , 2010, PloS one.

[21]  C. Pham,et al.  Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. , 2002, The Journal of clinical investigation.

[22]  B. Pazár,et al.  Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice. , 2011, Arthritis and rheumatism.

[23]  Karan Sharma,et al.  Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. , 2008, Immunity.

[24]  P. Naccache,et al.  Crystal‐induced neutrophil activation , 2010, Immunology and cell biology.

[25]  G. Núñez,et al.  Cutting Edge: Critical Role for Mesothelial Cells in Necrosis-Induced Inflammation through the Recognition of IL-1α Released from Dying Cells1 , 2008, The Journal of Immunology.

[26]  Richard A. Flavell,et al.  The Nalp3 inflammasome is essential for the development of silicosis , 2008, Proceedings of the National Academy of Sciences.

[27]  J. Bertin,et al.  Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. , 2006, Immunity.

[28]  T. Ley,et al.  Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Block,et al.  Hyperuricemia induces endothelial dysfunction. , 2005, Kidney international.

[30]  M. Su,et al.  Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. , 1995, Science.

[31]  R. Terkeltaub,et al.  Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. , 2004, Arthritis and rheumatism.

[32]  S. Akira,et al.  MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. , 2006, The Journal of clinical investigation.

[33]  R. Black,et al.  Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase , 1991, The Journal of experimental medicine.

[34]  G. Weissmann,et al.  Mechanisms of lysosomal enzyme release from leukocytes. IV. Interaction of monosodium urate crystals with dogfish and human leukocytes. , 1975, Arthritis and rheumatism.

[35]  A. Murphy,et al.  Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice. , 2010, Arthritis and rheumatism.

[36]  D. Goldfarb,et al.  Gout and its comorbidities. , 2010, Bulletin of the NYU hospital for joint diseases.

[37]  N. Bogavac-Stanojević,et al.  High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. , 2009, Atherosclerosis.

[38]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[39]  F M BURNET,et al.  Immunological recognition of self. , 1961, Science.

[40]  A. So,et al.  Extended Report , 2022 .

[41]  R. Germain,et al.  The biochemistry and cell biology of antigen processing and presentation. , 1993, Annual review of immunology.

[42]  Takahiko Nakagawa,et al.  A causal role for uric acid in fructose-induced metabolic syndrome. , 2006, American journal of physiology. Renal physiology.

[43]  S. Akira,et al.  Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.

[44]  Shubhada Sankararaman,et al.  Cells, tissues and disease: Principles of general pathology , 1997 .

[45]  J. Tschopp,et al.  Thioredoxin-interacting protein links oxidative stress to inflammasome activation , 2010, Nature Immunology.

[46]  C. Coban,et al.  Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. , 2011, Immunity.

[47]  Troy Krahl,et al.  Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry , 1998, Nature Medicine.

[48]  Christine E. Becker,et al.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes , 2010, Nature Immunology.

[49]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[50]  S. McColl,et al.  Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. , 1998, Blood.

[51]  J. Tschopp,et al.  Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence , 2009, Nature.

[52]  N. Sarvetnick,et al.  Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. , 2002, The Journal of clinical investigation.

[53]  A. Rossini,et al.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. , 1976, Science.

[54]  V. Kuchroo,et al.  CD28/B7 costimulation: a review. , 1998, Critical reviews in immunology.

[55]  J. Tschopp,et al.  Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. , 2012, Immunity.

[56]  G. Núñez,et al.  The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated IL‐1β secretion but dispensable for adjuvant activity , 2008, European journal of immunology.

[57]  E. Krishnan Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. , 2010, Rheumatology.

[58]  R. Terkeltaub,et al.  Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis , 2009, Annals of the rheumatic diseases.

[59]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[60]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[61]  R. Terkeltaub,et al.  Engagement of CD14 Mediates the Inflammatory Potential of Monosodium Urate Crystals1 , 2006, The Journal of Immunology.

[62]  A. So,et al.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.

[63]  H. Anders,et al.  The role of innate immunity in autoimmune tissue injury , 2008, Current opinion in rheumatology.

[64]  S. Bandinelli,et al.  Uric acid and inflammatory markers. , 2006, European heart journal.

[65]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[66]  L. Jahns,et al.  High proportions of foods recommended for consumption by United States Dietary Guidance contain solid fats and added sugar: results from the National Health and Nutrition Examination Survey (2007-2008) , 2014, Nutrition Journal.

[67]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[68]  Hyon K. Choi,et al.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.

[69]  M. Oosting,et al.  Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. , 2010, Arthritis and rheumatism.

[70]  G. Nuki Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation , 2008, Current rheumatology reports.

[71]  Moshe Arditi,et al.  Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. , 2012, Immunity.

[72]  K. Rock,et al.  How dying cells alert the immune system to danger , 2008, Nature Reviews Immunology.

[73]  D. Monack Faculty Opinions recommendation of Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. , 2008 .

[74]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[75]  P. Puddu,et al.  Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. , 2012, Journal of cardiology.

[76]  B. Kullberg,et al.  Pro‐inflammatory cytokines in patients with essential hypertension , 2001, European journal of clinical investigation.

[77]  Bernard Thorens,et al.  Uric acid transport and disease. , 2010, The Journal of clinical investigation.

[78]  Kaiwen Xiao,et al.  Serum uric acid levels in patients with multiple sclerosis: a meta-analysis , 2012, Neurological research.

[79]  R. Terkeltaub,et al.  Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[80]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[81]  K. Rock,et al.  Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[82]  H. Hammad,et al.  Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.

[83]  T. Mack,et al.  A revised estimate of twin concordance in systemic lupus erythematosus. , 1992, Arthritis and rheumatism.

[84]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[85]  K. Rock,et al.  Identification of the Cellular Sensor That Stimulates the Inflammatory Response to Sterile Cell Death , 2010, The Journal of Immunology.

[86]  G. Weissmann,et al.  Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. , 1995, The Journal of clinical investigation.

[87]  J. Tschopp,et al.  Malarial Hemozoin Is a Nalp3 Inflammasome Activating Danger Signal , 2009, PloS one.

[88]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[89]  K. Rock,et al.  The inflammatory response to cell death. , 2008, Annual review of pathology.

[90]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[91]  E. Latz The inflammasomes: mechanisms of activation and function. , 2010, Current opinion in immunology.

[92]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[93]  F. Sutterwala,et al.  Sensing damage by the NLRP3 inflammasome , 2011, Immunological reviews.

[94]  R. Terkeltaub,et al.  TLR2 Signaling in Chondrocytes Drives Calcium Pyrophosphate Dihydrate and Monosodium Urate Crystal-Induced Nitric Oxide Generation1 , 2005, The Journal of Immunology.

[95]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[96]  P. Hawkins,et al.  Hereditary auto-inflammatory disorders and biologics , 2006, Springer Seminars in Immunopathology.

[97]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[98]  Grace Y Chen,et al.  Sterile inflammation: sensing and reacting to damage , 2010, Nature Reviews Immunology.

[99]  P. Ricciardi-Castagnoli,et al.  Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. , 1998, Journal of immunology.

[100]  B. Álvarez-Lario,et al.  Uric acid and evolution. , 2010, Rheumatology.

[101]  K. Rock,et al.  Natural endogenous adjuvants , 2004, Springer Seminars in Immunopathology.

[102]  J. Tschopp,et al.  Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β , 2010, Proceedings of the National Academy of Sciences.

[103]  K. Rock,et al.  Cutting Edge: Elimination of an Endogenous Adjuvant Reduces the Activation of CD8 T Lymphocytes to Transplanted Cells and in an Autoimmune Diabetes Model , 2006, The Journal of Immunology.

[104]  R. Flavell,et al.  NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy , 2011, Proceedings of the National Academy of Sciences.

[105]  G. Paré,et al.  Crystal-Induced Neutrophil Activation: XI. Implication and Novel Roles of Classical Protein Kinase C1 , 2009, The Journal of Immunology.

[106]  P. Lipsky,et al.  Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. , 1993, The Journal of biological chemistry.

[107]  M. Karin,et al.  Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. , 2009, Arthritis and rheumatism.

[108]  F. Martinon,et al.  Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration , 2007, Cell Death and Differentiation.

[109]  R. Thiele,et al.  The pathogenesis of bone erosions in gouty arthritis , 2010, Annals of the rheumatic diseases.

[110]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[111]  C. Kurts,et al.  Brief Definitive Report Major Histocompatibility Complex Class I–restricted Cross-presentation Is Biased towards High Dose Antigens and Those Released during Cellular Destruction , 2022 .

[112]  C. Coeshott,et al.  Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[113]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[114]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[115]  F. Schmidt Meta-Analysis , 2008 .

[116]  R. Koike,et al.  Cryopyrin-associated periodic syndromes: background and therapeutics , 2010, Modern rheumatology.

[117]  F. Re,et al.  Cutting Edge: Inflammasome Activation by Alum and Alum’s Adjuvant Effect Are Mediated by NLRP31 , 2008, The Journal of Immunology.

[118]  J. Tschopp,et al.  Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. , 2009, American journal of respiratory and critical care medicine.

[119]  A. Goldberg,et al.  Proteolysis and class I major histocompatibility complex antigen presentation , 1999, Immunological reviews.

[120]  G. Weissmann,et al.  Mechanisms of lysosomal enzyme release from leukocytes. IV. Interaction of monosodium urate crystals with dogfish and human leukocytes. , 1975, Arthritis and rheumatism.

[121]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.

[122]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[123]  B. Fu,et al.  Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. , 2012, Cell calcium.

[124]  A. Taniguchi,et al.  Comorbidities in Patients with Gout , 2011, Nucleosides, nucleotides & nucleic acids.

[125]  T. Nakagawa,et al.  Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. , 2002, American journal of physiology. Renal physiology.

[126]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[127]  Roddy Edward,et al.  Gout , 2011 .

[128]  Eka Swadiansa The hypothesis , 1990 .

[129]  K. Rock,et al.  Uric acid promotes an acute inflammatory response to sterile cell death in mice. , 2010, The Journal of clinical investigation.

[130]  K. Moore,et al.  The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.

[131]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[132]  R. Kolodner,et al.  Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome , 2001, Nature Genetics.

[133]  J. Hughes,et al.  Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism , 2001, Hypertension.

[134]  J. Singh,et al.  Anakinra for Rheumatoid Arthritis: A Systematic Review , 2009, The Journal of Rheumatology.

[135]  S. Cullen,et al.  Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. , 2011, Molecular cell.

[136]  Xiangmei Zhou,et al.  A role for mitochondria in NLRP3 inflammasome activation , 2011, Nature.

[137]  A. Struthers,et al.  Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.

[138]  L. Joosten,et al.  Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. , 2009, Arthritis and rheumatism.

[139]  D. Mccarty Urate crystals, inflammation, and colchicine. , 2008, Arthritis and rheumatism.

[140]  E. Block,et al.  Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. , 2008, American journal of physiology. Cell physiology.

[141]  A. Porter,et al.  Critical role for cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and caspase-1-independent necrosis triggered by the microbial toxin nigericin , 2003, Cell Death and Differentiation.